News

Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, announced it has expanded its pipeline via the…
Read More...

Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, announced a multi-year collaboration…
Read More...

Koselugo (selumetinib) has been approved in Japan for the treatment of paediatric patients three years of age and older with plexiform neurofibromas (PNs) in neurofibromatosis type 1…
Read More...

Merck known as MSD outside of the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and…
Read More...

Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design platform for genetic medicine, announced a strategic collaboration with Sanofi for the use of…
Read More...

Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease and SynerK, a leading RNAi…
Read More...

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced the dosing with ATA-100 of a first…
Read More...

Pulse Biosciences, Inc. a novel bioelectric medicine company developing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, announced receipt of U.S. Food and Drug…
Read More...

Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster…
Read More...

Seagen Inc. and LAVA Therapeutics N.V. announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced…
Read More...

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the U.S. Food…
Read More...

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary…
Read More...

Massive Bio, which uses its proprietary artificial intelligence-based platform to match cancer patients to clinical trials regardless of where they live or their financial…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent…
Read More...

Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are…
Read More...

GSK plc and Spero Therapeutics, Inc. announced they have entered into an exclusive licence agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being…
Read More...

Pfizer Inc. announced an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets) to Global Fund as…
Read More...

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), announced an exclusive collaboration…
Read More...

Coeptis Therapeutics, Inc. announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology…
Read More...

Clearmind Medicine Inc.  a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it…
Read More...